The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 181, 6850 -6858
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drake, P. M.
Right arrow Articles by Bertozzi, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drake, P. M.
Right arrow Articles by Bertozzi, C. R.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Stem Cells

Polysialic Acid, a Glycan with Highly Restricted Expression, Is Found on Human and Murine Leukocytes and Modulates Immune Responses1

Penelope M. Drake*, Jay K. Nathan*, Christina M. Stock*, Pamela V. Chang*, Marcus O. Muench§, Daisuke Nakata, J. Rachel Reader||, Phung Gip{dagger}, Kevin P. K. Golden*, Birgit Weinhold#, Rita Gerardy-Schahn#, Frederic A. Troy, II and Carolyn R. Bertozzi2,*,{dagger},{ddagger}

* Department of Chemistry and {dagger} Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720; {ddagger} Howard Hughes Medical Institute, San Francisco, CA 94143; § Blood Systems Research Institute, San Francisco, CA 94118 and Department of Laboratory Medicine, University of California, San Francisco, CA 94121; Department of Biochemistry and Molecular Medicine, School of Medicine and the || Comparative Pathology Laboratory, School of Veterinary Medicine, University of California, Davis, CA 95616; and # Abteilung Zelluläre Chemie, Zentrum Biochemie, Medizinische Hochschule Hannover, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Polysialic acid (polySia) is a large glycan with restricted expression, typically found attached to the protein scaffold neural cell adhesion molecule (NCAM). PolySia is best known for its proposed role in modulating neuronal development. Its presence and potential functions outside the nervous systems are essentially unexplored. Herein we show the expression of polySia on hematopoietic progenitor cells, and demonstrate a role for this glycan in immune response using both acute inflammatory and tumor models. Specifically, we found that human NK cells modulate expression of NCAM and the degree of polymerization of its polySia glycans according to activation state. This contrasts with the mouse, where polySia and NCAM expression are restricted to multipotent hematopoietic progenitors and cells developing along a myeloid lineage. Sialyltransferase 8Sia IV–/– mice, which lacked polySia expression in the immune compartment, demonstrated an increased contact hypersensitivity response and decreased control of tumor growth as compared with wild-type animals. This is the first demonstration of polySia expression and regulation on myeloid cells, and the results in animal models suggest a role for polySia in immune regulation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Polysialic acid (polySia)3 is an unusual glycan by almost any definition. Structurally, it comprises repeating sialic acid monomers with {alpha}2,8 linkages. Its size in terms of monosaccharide units, or degree of polymerization (DP), is large, with reported values of 50–150 ranging up to >370 residues (1, 2). This contrasts with the typical N-linked glycan containing 10–12 monomers, and is similar to glycosaminoglycans (GAGs), which average 80–100 residues (3). The synthesis of polySia is also unusual: an entire chain is produced by a single enzyme acting on classical N-linked and, less commonly, O-linked core structures. Two polysialyltransferases, ST8Sia IV (PST) and ST8Sia II (STX), with distinct expression patterns are involved in synthesis of polySia. In contrast, the synthesis of most glycans requires the coordinated action of many enzymes. Therefore, while glycan structure is difficult to track genetically, polySia can be localized by the expression patterns of ST8Sia IV and ST8Sia II. Furthermore, while many glycan structures can modify any number of protein cores, the polysialyltransferases appear to be highly selective in their scaffold choices. Aside from autopolysialylation of the ST8Sia IV and ST8Sia II enzymes, only four other protein carriers have been identified: the neural cell adhesion molecule (NCAM, also termed CD56), the {alpha}-subunit of the voltage-gated sodium channel, CD36, and neuropilin (4, 5, 6, 7). Of these, NCAM is by far the most commonly used scaffold.

Polysialylated NCAM is prominent in the developing nervous system, where it has been most extensively studied. A large body of work has shown that polySia affects neuronal functions as varied as migration (8, 9), cytokine response (9, 10), and cell contact-dependent differentiation (11). Provocatively, these same functions are vital components of immune function. Leukocytes migrate throughout the body, guided by specialized cytokines, termed chemokines, to effect both homeostatic and inflammatory functions that are often dictated through cytokine and cell contact-dependent signals.

Intriguingly, expression of both ST8Sia IV and ST8Sia II has been documented in the immune system, suggesting that polySia is abundant therein. In the adult human, primary and secondary lymphoid organs including the placenta, spleen, thymus, intestine, and peripheral blood express ST8Sia IV, while ST8Sia II is produced in the thymus (12). Our recent work in the mouse suggests that polySia plays an important role in progenitor trafficking to the thymus (P. M. Drake, manuscript submitted). Furthermore, NCAM (CD56) is expressed on two subsets of mature human lymphocytes: NK cells and NKT cells. Although NCAM has long been used as a marker for these cell populations (13), its functional role remains undefined. We postulated that in the immune system NCAM functions as a scaffold for presentation of polySia, and that the glycan itself confers function to this glycoprotein. Moreover, the functional significance of these observations is unknown.

The documented role of polySia in modulating cell adhesion, migration, and cytokine response in the nervous system motivated us to investigate the possibility of analogous functions in the immune system. Herein, we describe polySia expression on NCAM in human NK cells, as well as mouse hematopoietic progenitors and myeloid cells. In support of a role for polySia in the immune system, we demonstrate that human NK cells regulate the expression and length of polySia with activation state, and that ST8Sia IV–/– mice have aberrant contact hypersensitivity responses and enhanced tumor growth as compared with wild-type mice.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

Wild-type C57BL/6 and congenic GFP+ mice were purchased from The Jackson Laboratory. Mice were housed in specific pathogen-free conditions. Experiments were approved by the University of California at Berkeley’s Animal Care and Use Committee. The generation of ST8Sia IV–/– and ST8Sia II–/– mice has been described (14, 15).

Human NK cell analysis

Human leukocytes were obtained as buffy coats from the American Red Cross, Oakland, CA. PBMCs were prepared as described (16). NK cells were isolated using a magnetic bead-based method (Dynal NK cell negative isolation kit, Invitrogen). Cells were either lysed directly or cultured in RPMI 1640 with 10% FBS. Endoneuraminidase N (Endo N, 1/1000 to 1/2000 dilution) and/or 6000 U/ml recombinant IL-2 (National Cancer Institute Preclinical Repository) were added as indicated.

Human bone marrow analysis

Human fetal bone marrow was obtained from elective pregnancy terminations at the University of California San Francisco with approval of the Committee for Human Research. Bone marrow was harvested from long bones as previously described (17). Light-density cells were isolated by centrifugation on a layer of 1.077 g/ml NycoPrep (Axis-Shield). Both total and light-density cell fractions were studied.

Assessment of polySia polymerization

Human NK cell cultures were pelleted, flash frozen, and stored at –80°C until analysis. Pellets from five individual donors were combined, and the degree of polymerization was determined as described (2).

Antibodies

Abs used for flow cytometry are as follows. From eBioscience: fluorescein-conjugated anti-CD3{epsilon} (145-2C11), anti-CD4 (GK1.5), anti-CD11b (M1/70), anti-CD25 (PC61.5), anti-TCRβ (H57–597), anti-Gr-1 (RB6–8C5), and anti-TER119; PE-Cy5-conjugated Sca-1 (D7), and isotype control rat IgG2a; and allophycocyanin-conjugated secondary anti-mouse IgG. From BD Biosciences: purified anti-polySia (12F8), anti-NCAM (NCAM-13), and rat IgM isotype control; fluorescein-conjugated anti-CD8a (53-6.7) anti-TCR{gamma}{delta} (GL3), anti-NK1.1 (PK136), anti-B220 (RA3-6B2), and isotype controls mouse IgG2a (G155-178), rat IgG1 (R3-34), rat IgG2a (R35-95), and rat IgG2b (A95-1); PE-conjugated anti-CD8a (53-6.7), anti-CD3 (SK7), anti-CD33 (Leu-M9), anti-CD81 (JS-81), anti-CD117 (104D2), anti-CD25 (PC61), and anti-CD117 (2B8) and isotype controls rat IgG1 (R3-34) and rat IgG2a (R35-95); PE-Cy5-conjugated anti-CD3 (17A2), anti-CD44 (IM7). From Jackson ImmunoResearch Laboratories: allophycocyanin-conjugated secondary anti-rat IgM. From Invitrogen: fluorescein-conjugated anti-CD3 (S4.1), anti-CD15 (V1MC6), anti-CD34 (581), and isotype control mouse IgM; PE-conjugated anti-CD7 (CD7-6B7), anti-CD34 (581), anti-CD45 (HI30), anti-CD105 (SN6), and isotype controls mouse IgG1, mouse IgG2a, and mouse IgG2b. From Beckman Coulter: PE-conjugated anti-CD2 (SFCI3Pt2H9-T11). From Exalpha Biologicals: fluorescein-conjugated anti-CD56 (C5.9). The production of mAb 735 has been described (18).

Flow cytometry and sorting

Cells were isolated and immediately incubated for 10 min with mouse BD Fc block (anti-Fc{gamma}III/IIR; BD Biosciences), followed by the addition of Abs for staining. After 20 min cells were washed twice in PBS and analyzed on a FACSCalibur (BD Biosciences) using CellQuest (BD Biosciences) software. Hematopoietic stem cells were defined as Lin– (including TER119, CD3, CD4, CD8, B220, NK1.1, Gr-1, TCRβ, TCR{gamma}{delta}, CD11b), c-Kit+, Sca-1+. Human cells were analyzed on an LSR II flow cytometer (BD Biosciences). Metaanalyses were performed using FlowJo software (Tree Star). Differences between controls, which were stained with an irrelevant Ab of the same isotype, and the experimentals, which expressed polySia, were calculated using the population comparison function of FlowJo software. For sorted cells, freshly isolated mouse bone marrow was centrifuged over a layer of Ficoll-Paque Plus (Amersham Biosciences), and then light-density cells were labeled with anti-c-Kit (PE) and purified anti-polySia (12F8) followed by anti-rat IgM (allophycocyanin). Desired cell subsets were sorted using a Dako-Cytomation MoFlo high-speed sorter (Dako) or a FACSAria (BD Biosciences).

Colony-forming cell assays

Erythroid progenitor cultures were initiated in septuplicate with 2.5 x 102 to 2.0 x 103 cells/dish. Colony-forming cell assays were performed as previously described (19) in serum-deprived medium with substitution of 10% FBS for low-density lipoprotein (HyClone Laboratories). Growth was supported by 100 ng/ml recombinant rat stem cell factor (Amgen) and 10 U/ml recombinant human (rh) erythropoietin (Amgen). After 7 days, cultures were scored for burst-forming units erythroid identified as distinct clusters of erythroid cells with or without myeloid cells and myeloid colony-forming cells having a dispersed cell morphology. Myeloid progenitors were assayed as previously described (20). Sorted cells were cultured, in triplicate, at 1.0 x 102 to 2.0 x 103 cells/dish in the described medium containing 100 ng/ml recombinant rat stem cell factor, 20 ng/ml rhIL-6, 20 ng/ml recombinant murine IL-3, 20 ng/ml rhM-CSF (R&D Systems), and 20 ng/ml rhG-CSF (Amgen). After 7 days, cultures were scored visually for colonies (50+ cells) and clusters (10–49 cells). The erythroid and myeloid assays were repeated twice with similar results.

Lymphoid progenitor assay

OP9 cells transfected with Delta-like-1 (DL1) and GFP, or with GFP alone, were kindly provided by Dr. Juan Carlos Zúñiga-Pflücker (Sunnybrook & Women’s Research Institute). OP9-GFP and OP9-DL1 cells were cultured and passaged as described (21). Sorted bone marrow subsets were plated onto a semiconfluent layer of either OP9-GFP or OP9-DL1 cells in complete DMEM-10 with 1 ng/ml IL-7 (R&D Systems) and 5 ng/ml Flt-3 ligand (R&D Systems). Cocultures were maintained, passaged as described (21), and harvested at 18 days. Cells were counted with a hemocytometer and analyzed by flow cytometry for expression of lineage markers. The experiment was repeated three times with similar results.

5-Fluorouracil (5-FU) recovery

Wild-type mice (6–8 wk) received a single i.p. dose of either 5-FU (150 mg/kg) or vehicle. Following drug administration, bone marrow was harvested from two to three mice at each time point (days 1, 2, 7, 10, and 12) for flow cytometric analyses. The experiment was repeated three times with similar results.

G-CSF response

Wild-type mice (6–8 wk) were injected i.p. once a day for 5 days with 100 µl of either vehicle (PBS + 2% BSA) or vehicle containing 2 µg G-CSF. Mice, two to three per group, were sacrificed after 5 days. Bone marrow was harvested for analysis by flow cytometry. The experiment was repeated three times with similar results.

Immunoblotting

Freshly isolated mouse bone marrow and brain samples were disrupted on ice in 20 mM Tris-Cl (pH 8.0), 140 mM NaCl, 10% glycerol, 1% Nonidet P-40, 2 mM EDTA, 10 mM NaF, and proteinase inhibitor cocktail (Calbiochem). Lysates were separated on a 3–8% Tris-acetate gel (Bio-Rad), transferred to nitrocellulose (Bio-Rad), and nonspecific reactivity was blocked by incubating the blots for 2 h in 5% milk in PBS with 0.05% Tween 20 (PBST). Blots were then incubated overnight at 4°C in PBST with primary Ab at 1/5000 (anti-polySia, mAb 735) or 1/500 (anti-NCAM, mAb NCAM-13). After washing three times for 5 min in PBST, blots were incubated for 90 min at room temperature in PBST with HRP-conjugated secondary Abs (Jackson ImmunoResearch Laboratories) at 1/5000. Blots were washed three times for 5 min in PBST and signal was detected using SuperSignal West Pico chemiluminescence substrate (Pierce).

Immunoprecipitation

Bone marrow lysates were prepared as described above from 10 wild-type and 10 ST8Sia IV–/– mice, and precleared by a 30-min incubation at 4°C with protein G-Sepharose beads (Invitrogen). Ab-conjugated beads were prepared by incubating 5 µg mAb 735 with 50 µl protein G-Sepharose beads at 4°C. mAb 735-conjugated beads were added to lysates and tumbled for 1 h at 4°C. Following incubation, beads were washed extensively in ice-cold wash buffer [0.1% Triton X-100, 50 mM Tris-Cl (pH 7.4), 300 mM NaCl, 5 mM EDTA, 0.02% NaN3 (w/v)] and then in ice-cold PBS. PolySia was removed from captured proteins by direct treatment with 2 µl of Endo N (3 h at 37°C). Then, the sample was boiled in sample buffer (XT sample buffer, XT reducing agent; Bio-Rad) and run on a 3–8% Tris-acetate gel (Bio-Rad). Bands were visualized with a mass spectrometry-compatible silver stain (Silver Quest; Invitrogen).

Protein digestion and identification by mass spectrometry

The preparation and analysis of samples were performed at the Taplin Biological Mass Spectrometry Facility, Harvard Medical School. Silver-stained bands were excised and digested with trypsin, and analyzed by ESI-LC-MS/MS on an LTQ linear ion-trap mass spectrometer (ThermoFisher Scientific). Peptide sequences (and hence protein identity) were determined by matching protein databases with the acquired fragmentation pattern by the software program Sequest (ThermoFisher Scientific) (22). Spectral matches were manually examined and multiple identified peptides per protein were required.

In vivo progenitor assay

ST8Sia IV–/– mice were crossed with congenic wild-type mice expressing GFP (stock 004353, The Jackson Laboratory). F1 progeny were back-crossed with ST8Sia IV–/– animals to yield ST8Sia IV–/–;GFP+/– mice, which were used as bone marrow donors for these studies. Genotype was confirmed by PCR as previously described (14). Sorted cell populations were mixed with 1 x 106 whole wild-type bone marrow cells for injection. Wild-type recipient mice (three per donor subset) were irradiated with one dose of 900 rad and injected i.v. with prepared cells. After 21 days, recipients were sacrificed and their lymphoid organs analyzed for GFP+ cells. The experiment was repeated twice with similar results.

Contact hypersensitivity (CHS)

2,4-Dinitrofluorobenzene (DNFB) was used to induce CHS in wild-type or ST8Sia IV–/– mice (3–10 mice per group). Animals were sensitized by painting bare abdominal skin on 2 consecutive days with 20 µl of 0.5% DNFB in acetone/olive oil (4/1). Mice were challenged 7 days later with an application of 20 µl of 0.5% DNFB on the right ear, and vehicle alone on the left ear. The inflammatory response was assessed by measuring ear thickness with digital calipers at 24, 48, and 72 h. In some cases, animals were euthanized and their ears removed for histological evaluation. The experiment was repeated four times with similar results.

Tumor challenge

Mouse RMA and RMA-S (which have reduced MHC class I expression) NKT cell tumor cell lines were obtained from the American Type Culture Collection. Each experimental group (wild-type and ST8Sia IV–/–) contained 5–10 mice (4–12 wk) that were age-matched within 2 wk. RMA or RMA-S cells (104-105) were injected s.c. into the flank. Palpable tumors were measured daily with digital calipers. Mice were euthanized after loss of >20% of original body weight, when a tumor reached >1.5 cm or became ulcerated. Animals surviving 60 days were considered tumor-free. The experiment was repeated twice with similar results.

Hematology and histology

The Univeristy of California Davis Comparative Pathology Laboratory performed complete blood counts, which were validated by visual examination of blood smears. Histological evaluation of CHS ear specimens was also performed.

Statistics

Unless otherwise stated, numbers represent the means ± 1 SD.

Statistical significance in tumor assays was calculated using a two-tailed Mann-Whitney U test. Statistical significance of the remaining data was calculated using an unpaired two-tailed Student’s t test. p < 0.05 was considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Human NK cells modulate NCAM protein expression and degree of polysialylation with activation state

Flow cytometric analyses showed that human PBMCs expressed the NCAM protein scaffold and its polysialic acid modifications, which were sensitive to the polySia-specific neuraminidase Endo N (Fig. 1A). Upon activation with IL-2, the cell-surface levels of both the underlying protein and the attached glycan increased (Fig. 1B; n = 10). To address whether the observed increase in polySia expression reflected differential proliferation of CD56dim and CD56bright NK cell populations during the assay, sorted cells with these phenotypic characteristics were analyzed in parallel; similar responses were observed (data not shown). These data suggest that polySia levels are regulated by NK cell activation.


Figure 1
View larger version (49K):
[in this window]
[in a new window]

  		FIGURE 1. NCAM/CD56+ human NK cells modulate polySia and NCAM expression with activation. Flow cytometric analyses of total PBMCs after 24 h in culture with (right) or without (left) the polySia-specific neuraminidase Endo N (A) and of total PBMCs after 48 h culture in the presence (heavy line, no fill) or absence (light line, gray fill) of IL-2 (B).

 
As the DP of polySia on human primary cells has not been explored, purified NK cells were cultured with or without IL-2 for 48 h. Samples from five individual donors were combined for analysis. Intact polySia chains on glycan cores containing lactosamine were released by endo-β-galactosidase treatment. This method may have neglected to free polySia that was attached to NCAM through alternate core structures; however, the relative amounts of total sialic acid released from resting and activated NK cells were in accord with our flow cytometry (Fig. 1) and immunoblotting data (not shown). The liberated polySia was analyzed by HPLC as previously described to determine chain length (2). Total sialic acid content [as N-acetyl neuraminic acid (NANA)] of HPLC fractions was monitored to track the relative abundance of each DP population. In both resting and activated NK cells, a large fraction of total NANA was associated with small non-polySia glycans (DP 1–10), most likely reflecting the capping groups of typical N- and O-linked glycans. Plotting percentage of total NANA vs DP showed that activation of NK cells increased the abundance of NANA associated with polySia (Fig. 2). Additionally, chain length, which was extremely heterogeneous on resting cells, was compressed into the middle range (DP 11–140) upon activation.


Figure 2
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 2. Human NK cell activation results in an increased production of short to medium-length polySia chains. Purified primary NK cells from five individual donors were cultured separately for 48 h with or without IL-2, combined and analyzed for DP. Fractions of increasing DP were collected (x-axis) and analyzed for total sialic acid (as NANA) content (y-axis).

 
ST8Sia IV catalyzes polySia expression by populations of mouse bone marrow cells during myeloid differentiation

To analyze the potential immunological properties of polySia, we used a mouse model. First, we characterized the expression patterns of polySia on immune subsets in wild-type animals. In contrast to their human counterparts, polySia was not detectable on mouse NK cells (Fig. 3C). This finding was consistent with RT-PCR analyses on sorted NK cells that revealed an absence of NCAM and ST8Sia IV (data not shown). Interestingly, robust polySia expression was detected on wild-type mouse bone marrow subsets (Fig. 3A). This expression was conserved in ST8Sia II–/– mice but absent in ST8Sia IV–/– mice, indicating that the latter enzyme was responsible for polySia on these cells.


Figure 3
View larger version (45K):
[in this window]
[in a new window]

  		FIGURE 3. ST8Sia IV produces polySia on subsets of mouse bone marrow and peripheral myeloid cells. Flow cytometric analyses of total wild-type (WT) bone marrow comparing polySia and c-Kit expression (A). We studied four populations: PSAneg/Kithigh (1), PSAlow/Kithigh (2), PSAhigh/Kithigh (3), and PSAlow/Kitlow (4). These subsets were present in ST8Sia II–/– mice, but absent from ST8Sia IV–/– animals. In the periphery (B), wild-type Gr-1+ myeloid cells expressed polySia, while the ST8Sia IV–/– cells displayed fluorescence similar to that of the isotype control. In contrast to the human, mouse NK cells did not express polySia (C). DX5+ splenocytes were labeled with isotype control (light line, gray fill) or anti-polySia (heavy line, no fill) Abs and analyzed by flow cytometry.

 
Bone marrow polySia expression correlated with receptor tyrosine kinase c-Kit expression, suggesting that the polySia+ cells were hematopoietic progenitors. We defined four subsets according to their relative levels of polySia (PSA) and c-Kit (Kit) (PSAneg/Kithigh, PSAlow/Kithigh, PSAhigh/Kithigh, PSAlow/Kitlow; Fig. 3A). The populations comprised 12%, 6%, 12%, and 42%, respectively, of total c-Kit+ bone marrow cells. Extensive phenotypic analyses by flow cytometry suggested that these subsets comprised cells that were differentiating along a myeloid pathway (Table I). The PSAneg/Kithigh population included hematopoietic stem cells (defined as Lin–, c-Kit+, Sca-1+) and most appeared to be progenitors as they were Lin– and expressed CD34. The second population (PSAlow/Kithigh) comprised more committed progenitors with near uniform expression of CD34, and to a lesser extent CD11b and Gr-1. As differentiation proceeded, evidenced by a reduction in CD34 expression and an increase in CD11b and Gr-1 expression, PSA levels dramatically increased in parallel (PSAhigh/Kithigh). The fully differentiated progeny (CD34+/–, CD11b+, Gr-1high) had polySia levels that were comparable to the progenitors (PSAlow/Kitlow). Consistent with the latter population containing mature myeloid cells, we found low levels of polySia expression on peripheral wild-type, but not ST8Sia IV–/–, Gr-1+ splenocytes (Fig. 3B). Thus, myeloid differentiation is characterized by a wave of high levels of polySia expression. In contrast to the mouse, human fetal bone marrow did not contain these polySia+ myeloid populations, and human peripheral myeloid cells did not express polySia (data not shown). The polySia+ subset in human fetal bone marrow consisted of NK cells, as determined by the phenotype: CD56+, CD7+, CD33–, and CD34– (data not shown). Note that the observed differences between adult mouse bone marrow and fetal human bone marrow may be attributable to variations in polySia expression during development.


View this table:
[in this window]
[in a new window]

  		Table I. Expression of Ags analyzeda

 
In vitro progenitor studies confirm the phenotypic analyses of the polySia expressing subsets

To confirm the phenotypic analyses, the bone marrow populations defined by polySia and c-Kit were sorted by flow cytometry and tested in vitro and in vivo for their ability to give rise to various immune lineages. For these experiments, the PSAneg/Kithigh subset served as a positive control, as hematopoietic stem cells were contained in this population (data not shown). In colony-forming assays testing erythroid and myeloid potential, both the positive control and the progenitor subset, PSAlow/Kithigh, gave rise to these lineages, forming both erythroid blasts and colonies, as well as myeloid colonies and clusters (Figs. 4). Of the more differentiated populations, the immature myeloid cells, PSAhigh/Kithigh, showed an intermediate ability to form myeloid clusters and did not produce erythroid populations. The fully differentiated PSAlow/Kitlow cells did not produce colonies in either assay.


Figure 4
View larger version (34K):
[in this window]
[in a new window]

  		FIGURE 4. The PSAneg/Kithigh and PSAlow/Kithigh subsets contain erythroid and myeloid progenitors. PolySia (PSA)/c-Kit-defined subsets were sorted from wild-type bone marrow and plated in culture using conditions that promote erythroid (A) or myeloid (B) development. A, Cells were maintained for 7 days in methyl-cellulose with erythropoietin, stem cell factor, and IL-3 and then analyzed microscopically for burst-forming units erythroid (BFU-E) and CFU granulocyte-macrophage (CFU-GM). BFU-E and CFU-GM counts were combined to determine the total number of colonies formed. B, Bone marrow cells were maintained in culture for 7 days and then scored microscopically for colonies (>50 cells) and clusters (10–49 cells). The results of two separate experiments are shown.

 
To test lymphoid progenitor potential, sorted bone marrow subsets were cocultured with OP9 cells transfected with a GFP vector control, or with GFP and the Notch ligand, DL1. In this assay, multipotent progenitors develop into B cells when cultured on OP9-GFP feeders, while DL1 induces T cell development. NK cells develop at lower efficiencies under both conditions. In accord with the phenotypic data and colony-forming assays, the positive control, PSAneg/Kithigh, and the progenitor population, PSAlow/Kithigh, produced all the lymphoid lineages, the latter with a 10-fold reduction in efficiency as compared with the former (Fig. 5). The immature myeloid subset, PSAhigh/Kithigh, did not produce NK or T cells and generated almost 1000-fold fewer B cells than the positive control population. The mature myeloid population, PSAlow/Kitlow, did not proliferate.


Figure 5
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 5. The PSAneg/Kithigh and PSAlow/Kithigh subsets contain lymphoid progenitors. PolySia (PSA)/c-Kit-defined subsets were sorted from wild-type bone marrow and placed in coculture with OP9 stromal cells expressing either GFP and DL1 or GFP alone. OP9-DL1 promotes the differentiation of lymphoid progenitors into T cells and NK cells, while OP9-GFP supports the development of B cells and NK cells. Differentiation was monitored by flow cytometry; results after 18 days in culture are shown. B cells were identified by B220 expression, and NK cells by cell surface DX5. T cell development was monitored by appearance of double-negative stage 2 and 3 cells, identified by expression of CD44 and CD25. Representative data from one experiment are shown. The experiment was repeated three times with similar results.

 
In vivo progenitor studies confirm the phenotypic and in vitro analyses of the polySia expressing subsets

For in vivo experiments, GFP+ congenic wild-type mice were used as donors so that engrafted lineages could be identified using this fluorescent reporter. Flow-sorted bone marrow subsets (~28,000 cells/mouse) were injected with a survival dose (1 x 106 cells/mouse) of wild-type bone marrow into irradiated wild-type recipient animals. Three weeks later mice were sacrificed and organs analyzed for GFP+ populations (Table II). Both the positive control, PSAneg/Kithigh, and the progenitor population, PSAlow/Kithigh, gave rise to erythroid (TER119+), myeloid (Gr-1+ and CD14+), and lymphoid (DX5+ and B220+) cells in the bone marrow and spleen. No statistically significant differences were noted in the numbers of cells recovered from these two donor populations. In contrast, the numbers of GFP+ cells isolated from the immature myeloid subset, PSAhigh/Kithigh, and the mature myeloid population, PSAlow/Kitlow, were reduced by an average of ~40-fold and ~500-fold, respectively, as compared with the progenitor subsets.


View this table:
[in this window]
[in a new window]

  		Table II. Number (x103) of recovered GFP+ cells expressing the designated cell-surface Ag/1000 transferred cells

 
Next, we asked whether development of the four bone marrow subsets was temporally linked. Mice were treated with one bolus of 5-FU to deplete cycling cells, and the disappearance and reappearance of the polySia/c-Kit-defined populations was followed over 12 days. As expected, the depletion and recovery of the progenitors preceded by 1 or 2 days that of the mature subsets (Fig. 6).


Figure 6
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 6. Development of the polySia (PSA)/c-Kit-defined subsets is temporally linked. Wild-type mice were injected with a single dose of 5-FU to deplete cycling cells, and then sacrificed at various intervals over a 12-day period. The loss and restoration of the PSA/c-Kit-defined subsets was monitored by flow cytometry.

 
Finally, we stimulated myeloid development and characterized the response of the bone marrow subsets. Briefly, wild-type mice were injected every 24 h with G-CSF for 5 days to induce expansion of the myeloid compartment, and bone marrow was analyzed by flow cytometry. In accord with the preceding phenotypic in vitro and in vivo data, both the progenitor population (PSAlow/Kithigh) and the immature and mature myeloid subsets (PSAhigh/Kithigh and PSAlow/Kitlow) significantly expanded in response to G-CSF treatment as compared with vehicle-treated control mice (p < 0.01; Fig. 7). Collectively, the data in Table II and Figs. 3–7 reveal that polySia expression is expressed and modulated during myeloid development in the mouse.


Figure 7
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 7. G-CSF increases the production of the PSAlow/Kithigh, PSAhigh/Kithigh, and PSAlow/Kitlow subsets. Wild-type mice were injected every 24 h with either vehicle alone or vehicle containing 2 µg of G-CSF. Animals were sacrificed after 5 days and polySia/c-Kit-defined bone marrow subsets were monitored by flow cytometry. The change in percentage of total bone marrow was calculated for each population. The results of two separate experiments were combined and plotted in this graph. *, p ≤ 0.007.

 
Given the expression of polySia on hematopoietic progenitors and myeloid cells, we asked whether there were obvious changes in the distribution of immune subsets in ST8Sia IV–/– as compared with wild-type mice. Hematological analyses revealed minimal differences: a statistically significant, slight increase in the percentage of lymphocytes in peripheral blood, and a corresponding although not significant decrease in the percentage of circulating monocytes and neutrophils (data not shown). No changes in the numbers or phenotype of peripheral myeloid lineages were noted (data not shown).

NCAM is the scaffold for myeloid expression of polySia

As this study was the first description of polySia on myeloid cells, the underlying protein scaffold was unknown. Candidate proteins that are expressed by other cell types that carry polySia modifications include NCAM and CD36. To identify the scaffold on the myeloid subsets that were the subject of this investigation, we immunoprecipitated wild-type and ST8Sia IV–/– bone marrow lysates with an anti-polySia Ab, treated the precipitatate with Endo N to remove polySia, and separated the deglycosylated proteins by SDS-PAGE. Following electrophoresis, two silver stained bands of ~120 and 140 kDa were observed in the wild-type, but not in the ST8Sia IV–/–, samples (Fig. 8A). The bands were excised and analyzed by electrospray mass spectrometry (LTQ linear ion trap), which identified both bands, on the basis of two peptides each, as NCAM (data not shown). In accord with this finding, both flow cytometry and immunoblotting confirmed the presence of NCAM on the relevant cells in mouse bone marrow (Fig. 8, B and C).


Figure 8
View larger version (84K):
[in this window]
[in a new window]

  		FIGURE 8. NCAM on the surface of mouse bone marrow cells is the scaffold for polySia. Polysialylated proteins were immunoprecipitated from lysates of wild-type (WT) or ST8Sia IV–/– (IV–/–) bone marrow (BM) cells and Endo N treated (A). Recovered proteins were silver stained and two bands were visible in wild-type, but not in ST8Sia IV–/–, samples. The bands were isolated and both were identified as NCAM, on the basis of two peptides each, by mass spectrometry. Flow cytometry using anti-NCAM and anti-c-Kit on wild-type mouse bone marrow cells showed NCAM was expressed on populations that were analogous to those observed by staining with anti-polySia and anti-c-Kit (B). Immunoblotting with anti-polySia and anti-NCAM mAbs showed a polySia signal in wild-type (WT) and ST8Sia II–/– bone marrow (BM), but not ST8Sia IV–/– bone marrow. In contrast, an NCAM signal was observed in association with all of the samples (C). Adult wild-type brain lysate was used as a positive control for both polySia and NCAM signals, and Endo N-treated (+EN) wild-type bone marrow was used as a negative control for polySia expression. Three major isoforms of NCAM were visible in brain lysates, while two (of ~140 and ~120 kDa) were present in bone marrow samples. Note that the polysialyated bands migrated with a lower mobility than those recognized by anti-NCAM, as only a fraction of this molecule carried these specialized glycans.

 
ST8Sia IV–/– mice exhibit exaggerated contact hypersensitivity and an inability to control growth of engrafted tumors

Next we tested immune responses in ST8Sia IV–/– mice. First, we used a CHS assay. Wild-type and ST8Sia IV–/– mice were sensitized with the hapten DNFB; a week later, they were challenged with an application of DNFB to one ear, and vehicle alone to the other ear. Wild-type mice responded as expected, with peak swelling observed around 24 h (23). Interestingly, the ST8Sia IV–/– response equaled or exceeded the wild-type response at 24 h, and inflammation continued to increase through 48 and 72 h. Fig. 9A shows the results of a representative experiment in which ST8Sia IV–/– ear thickness was statistically increased at all time points as compared with the response of wild-type animals.


Figure 9
View larger version (56K):
[in this window]
[in a new window]

  		FIGURE 9. The contact hypersensitivity response is excessive in ST8Sia IV–/– mice. Wild-type and ST8Sia IV–/– mice were sensitized to DNFB. One week later the left ear was treated with DNFB and the right ear with vehicle alone as a negative control. We assessed the inflammatory response by measuring ear thickness with digital calipers at 24, 48, and 72 h (A). Each ear measurement was taken three times. The data represent the average ear thickness ± SD for the DNFB-treated ears of all mice (n = 3 wild-type (WT), n = 3 ST8Sia IV–/–). At each time point, ST8Sia IV–/– mice had significantly more ear swelling than did wild-type animals (*, p = 0.01; **, p ≤ 0.001). Histological analyses showed excessive tissue damage observed in ST8Sia IV–/– mice as compared with wild-type mice (B). Vehicle- (i and ii) and DNFB-treated (iii and iv) ears were removed, fixed, sectioned, and stained with H&E for histological analysis. Asterisks denote areas of edema, which appeared as empty spaces. Bar = 60 µm.

 
We also assessed the CHS response at 72 h on a histological level and noted significantly more inflammation and edema after DNFB treatment of ST8Sia IV–/– mice as compared with controls, whose lesions were much less severe (Fig. 9B). Injury to the epithelium of ST8Sia IV–/– ears was also more pronounced, with diffuse epidermal hyperplasia, intercellular edema, and ulceration. The ST8Sia IV–/– vehicle-treated ears also demonstrated minimal to mild edema whereas the wild-type controls had no significant lesions.

We used immunosensitive and immunoresistant cell lines to test the response of ST8Sia IV–/– mice to a tumor challenge. RMA-S cells, which have reduced MHC class I expression, are sensitive to NK killing, while the parental RMA cells form tumors in wild-type animals (24). In initial experiments, RMA-S cells formed tumor masses in NK cell-depleted wild-type animals (25), but not wild-type or ST8Sia IV–/– mice. This finding suggested that the NK cell compartment of ST8Sia IV–/– mice was intact (data not shown). In contrast, injection of RMA cells into wild-type, ST8Sia IV–/–, or the immunodeficient TCRβ–/– mice led to uncontrolled tumor growth in all cohorts, requiring euthanasia of the animals when their tumors exceeded acceptable size limitations (Fig. 10). Importantly, tumor growth in ST8Sia IV–/– mice was significantly faster than in wild-type mice, and was comparable to the rate observed in TCRβ–/– mice (p < 0.02).


Figure 10
View larger version (14K):
[in this window]
[in a new window]

  		FIGURE 10. RMA tumors grow faster in ST8Sia IV–/– mice than in wild-type animals. Wild-type, ST8Sia IV–/–, and TCRβ–/– mice (negative controls for immunocompetence) were injected subcutaneously with 104-105 RMA cells. When tumors became ulcerated, or grew larger than 1.5 cm, or mice lost >20% of their original body weight, animals were sacrificed. Animals surviving more than 60 days were considered tumor-free; all deaths are plotted on the graph. There was a statistically significant difference in survival rates between wild-type and ST8Sia IV–/– animals (p = 0.02, two-tailed Mann-Whitney U test).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
PolySia expression and function have been extensively studied in the nervous system, but the distribution and role of polySia in the immune compartment is still undefined. Herein we demonstrated the presence of polySia on human NK cells and its absence on other immune subsets, a finding that is in accord with two earlier reports (26, 27). NK cells up-regulated the expression of polySia and its scaffold NCAM upon activation by IL-2 treatment. This coregulation suggested that the heightened polySia signals were due to an up-regulation of both scaffold and glycan, rather than solely attributable to expanded polySia chain length. In support of this conclusion, a comparison of DP on resting and activated cells showed that upon activation total polySia was increased and the DP became more homogenous, tending toward small- to medium-length chains. To our knowledge, this is the first elucidation of polySia DP on primary human cells. The DP values we observed were slightly larger than analogous structures that were isolated from cell lines and chick brain (1, 28). Although this distinction may be due to real differences among samples, it more likely reflects the fact that our method protects samples from acid-catalyzed internal hydrolysis. Importantly, this result shows that the size of polySia chains on human immune cells is comparable to that of GAGs, polysaccharides that play critical structural and functional roles in the extracellular matrix compartment. The repeating negative charge present on polySia is also reminiscent of highly anionic GAGs, and this characteristic is likely critical to its function.

Mouse NK cells did not express NCAM or polySia; however, both were coexpressed in mouse bone marrow. Immunoprecipitation of bone marrow lysates with anti-polySia Abs and identification of the resulting bands by mass spectrometry demonstrated that NCAM was the underlying scaffold. Analyses of ST8Sia II–/– and ST8Sia IV–/– mice indicated that the latter enzyme produced the glycan.

Flow cytometry revealed four bone marrow subsets based on expression of polySia and c-Kit. These populations (PSAneg/Kithigh, PSAlow/Kithigh, PSAhigh/Kithigh, PSAlow/Kitlow) bore cell surface Ags that were characteristic of myeloid differentiation. The PSAneg/Kithigh subset contained hematopoeitic progenitors, the PSAlow/Kithigh population, multipotent progenitors, and the PSAhigh/Kithigh, PSAlow/Kitlow groups, immature and mature myeloid cells, respectively. These findings were confirmed by in vitro and in vivo functional studies. 5-FU experiments demonstrated that the developmental kinetics of the four populations were temporally linked, and thus these populations shared a common lineage. Finally, the progenitor population, PSAlow/Kithigh, and the immature and mature myeloid subsets, PSAhigh/Kithigh and PSAlow/Kitlow, respectively, all expanded in response to treatment with G-CSF, further evidence that these populations are myeloid.

We observed a dramatic different in CHS response in ST8Sia IV–/–, which sustained augmented inflammation, as compared with wild-type. This striking observation elicits some interesting hypotheses. Considering possible roles for polySia in the immune system, we noted that both NK and myeloid cells are cytotoxic populations, carrying small positively charged antimicrobial peptides (AMPs) (29, 30, 31). Negatively charged GAGs such as heparan sulfate can bind and neutralize AMPs (32, 33), and thus it is possible that polySia with its structural similarities to GAGs has parallel activities. Expression of polySia on cytotoxic cells may localize AMPs released from leukocytes to prevent damage of surrounding tissues. The excessive CHS inflammatory response noted in ST8Sia IV–/– mice is consistent with this notion, as granulocytes that were initially drawn to the site might have injured tissues by uncontrolled AMP leakage. In turn, damaged tissue would release proinflammatory signals, upregulating the immune response (34). This cycle is consistent with the protracted inflammatory reaction, the increased tissue damage, and the elevated leukocytic infiltrate noted in ST8Sia IV–/– DNFB-treated ears relative to wild-type.

Additionally, GAGs, which bind cytokines and chemokines, modulate their availability and local concentration by either presenting or sequestering these molecules. It is possible that polySia plays a similar role. Studies in the nervous system have already demonstrated that neuronal responses to the cytokines brain-derived neurotrophic factor (BDNF) and platelet-derived growth factor (PDGF) are affected by polySia expression, although the mechanism has not been elucidated (9, 10). As the development and function of the immune system depend heavily on the influence of cytokines, polySia could have a great impact. However, its effects would likely be complex since cytokines that regulate signaling networks that, in turn, direct fate decisions, trafficking, and activation might be involved. The decreased immune response to ectopic tumors noted in ST8Sia IV–/– mice raises the intriguing possibility that these processes are influenced by polySia.

To our knowledge, this is the first demonstration of either polySia or NCAM expression on myeloid cells. The discovery of such expression in the mouse provides an opportunity to manipulate and study the immunological role of these molecules in a biological context, including in vivo models. The findings could have important implications for human health, as polySia and NCAM are not only expressed on human NK cells but also decorate the surfaces of a variety of tumors and bacteria. For instance, polysialylated NCAM, which is found on a number of cancers including gliomas, small-cell lung carcinomas, and Wilms’ tumors, is positively associated with metastasis and disease progression (35, 36, 37). We postulate that tumors co-opt the immune system’s strategy of using polySia to modulate responses to chemokines and growth factors, thus gaining a competitive advantage. Regarding bacteria, polySia expression is correlated with the virulence of pathogenic strains of Escherichia coli K1 and group B Neisseria meningitidis (38, 39). It is possible that bacterial polySia binds and neutralizes AMPs, sequestering them at a safe distance from the cell wall. Similarly, a subset of chemokines also has antibiotic activity (40), and polySia, which has been shown to modulate chemokine functions (9, 10), may protect bacteria from this threat. Collectively, our data point to a role for polySia in the complex processes involved in immunological development and host defense.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflicts of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 The research was made possible by a grant from the California Institute for Regenerative Medicine (CIRM, Grant RS1-00365). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of CIRM or any other agency of the State of California. Back

P.M.D. conceived and helped to perform and analyze all experiments. J.K.N. conducted immunoblotting and in vivo immunoassays. C.M.S. and K.P.K.G. executed in vivo immunoassays. P.V.C. performed 5'FU assays and flow cytometric analyses of peripheral myeloid cells. M.O.M. designed and executed in vitro colony-forming assays. D.N. and F.A.T. performed the DP analysis. J.R.R. provided pathological evaluation of ear sections. P.G. prepared and analyzed human NK cells. B.W. and R.G.-S. provided transgenic mice, mAb 735, and endoneuraminidase N. P.M.D. and C.R.B. wrote the manuscript.

2 Address correspondence and reprint requests to Dr. Carolyn R. Bertozzi, Department of Chemistry, B84 Hildebrand Hall No. 1460, University of California, Berkeley, CA 94720. E-mail address: crb{at}berkeley.edu Back

3 Abbreviations used in this paper: polySia, polysialic acid; CHS, contact hypersensitivity; DL1, Delta-like-1; DNFB, 2,4-dinitrofluorobenzene; DP, degree of polymerization; Endo N, endoneuraminidase N; 5-FU, 5-fluorouracil; GAG, glycosaminoglycan; NANA, N-acetyl neuraminic acid; NCAM, neural cell adhesion molecule; rh, recombinant human. Back

Received for publication June 12, 2008. Accepted for publication August 21, 2008.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Inoue, S., Y. Inoue. 2001. Developmental profile of neural cell adhesion molecule glycoforms with a varying degree of polymerization of polysialic acid chains. J. Biol. Chem. 276: 31863-31870. [Abstract/Free Full Text]
  2. Nakata, D., F. A. Troy, 2nd. 2005. Degree of polymerization (DP) of polysialic acid (polySia) on neural cell adhesion molecules (N-CAMS): development and application of a new strategy to accurately determine the DP of polySia chains on N-CAMS. J. Biol. Chem. 280: 38305-38316. [Abstract/Free Full Text]
  3. Varki, A., R. Cummings, J. Esko, H. Freeze, G. Hart, J. Marth. 1999. Essentials of Glycobiology Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  4. Curreli, S., Z. Arany, R. Gerardy-Schahn, D. Mann, N. M. Stamatos. 2007. Polysialylated neuropilin-2 is expressed on the surface of human dendritic cells and modulates dendritic cell-T lymphocyte interactions. J. Biol. Chem. 282: 30346-30356. [Abstract/Free Full Text]
  5. von Der Ohe, M., S. F. Wheeler, M. Wuhrer, D. J. Harvey, S. Liedtke, M. Muhlenhoff, R. Gerardy-Schahn, H. Geyer, R. A. Dwek, R. Geyer, et al 2002. Localization and characterization of polysialic acid-containing N-linked glycans from bovine NCAM. Glycobiology 12: 47-63. [Abstract/Free Full Text]
  6. Yabe, U., C. Sato, T. Matsuda, K. Kitajima. 2003. Polysialic acid in human milk. CD36 is a new member of mammalian polysialic acid-containing glycoprotein. J. Biol. Chem. 278: 13875-13880. [Abstract/Free Full Text]
  7. Zuber, C., P. M. Lackie, W. A. Catterall, J. Roth. 1992. Polysialic acid is associated with sodium channels and the neural cell adhesion molecule N-CAM in adult rat brain. J. Biol. Chem. 267: 9965-9971. [Abstract/Free Full Text]
  8. Murakami, S., T. Seki, U. Rutishauser, Y. Arai. 2000. Enzymatic removal of polysialic acid from neural cell adhesion molecule perturbs the migration route of luteinizing hormone-releasing hormone neurons in the developing chick forebrain. J. Comp. Neurol. 420: 171-181. [Medline]
  9. Zhang, H., L. Vutskits, V. Calaora, P. Durbec, J. Z. Kiss. 2004. A role for the polysialic acid-neural cell adhesion molecule in PDGF-induced chemotaxis of oligodendrocyte precursor cells. J. Cell Sci. 117: 93-103. [Abstract/Free Full Text]
  10. Vutskits, L., Z. Djebbara-Hannas, H. Zhang, J. P. Paccaud, P. Durbec, G. Rougon, D. Muller, J. Z. Kiss. 2001. PSA-NCAM modulates BDNF-dependent survival and differentiation of cortial neurons. Eur. J. Neurosci. 13: 1391-1402. [Medline]
  11. Petridis, A. K., A. El-Maarouf, U. Rutishauser. 2004. Polysialic acid regulates cell contact-dependent neuronal differentiation of progenitor cells from the subventricular zone. Dev. Dyn. 230: 675-684. [Medline]
  12. Angata, K., J. Nakayama, B. Fredette, K. Chong, B. Ranscht, M. Fukuda. 1997. Human STX polysialyltransferase forms the embryonic form of the neural cell adhesion molecule: tissue-specific expression, neurite outgrowth, and chromosomal localization in comparison with another polysialyltransferase, PST. J. Biol. Chem. 272: 7182-7190. [Abstract/Free Full Text]
  13. Lanier, L. L., R. Testi, J. Bindl, J. H. Phillips. 1989. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J. Exp. Med. 169: 2233-2238. [Abstract/Free Full Text]
  14. Eckhardt, M., O. Bukalo, G. Chazal, L. Wang, C. Goridis, M. Schachner, R. Gerardy-Schahn, H. Cremer, A. Dityatev. 2000. Mice deficient in the polysialyltransferase ST8SiaIV/PST-1 allow discrimination of the roles of neural cell adhesion molecule protein and polysialic acid in neural development and synaptic plasticity. J. Neurosci. 20: 5234-5244. [Abstract/Free Full Text]
  15. Angata, K., J. M. Long, O. Bukalo, W. Lee, A. Dityatev, A. Wynshaw-Boris, M. Schachner, M. Fukuda, J. D. Marth. 2004. Sialyltransferase ST8Sia-II assembles a subset of polysialic acid that directs hippocampal axonal targeting and promotes fear behavior. J. Biol. Chem. 279: 32603-32613. [Abstract/Free Full Text]
  16. Drake, P. M., M. D. Gunn, I. F. Charo, C. L. Tsou, Y. Zhou, L. Huang, S. J. Fisher. 2001. Human placental cytotrophoblasts attract monocytes and CD56bright natural killer cells via the actions of monocyte inflammatory protein 1{alpha}. J. Exp. Med. 193: 1199-1212. [Abstract/Free Full Text]
  17. Golfier, F., A. Barcena, M. R. Harrison, M. O. Muench. 2000. Fetal bone marrow as a source of stem cells for in utero or postnatal transplantation. Br. J. Haematol. 109: 173-181. [Medline]
  18. Frosch, M., I. Gorgen, G. J. Boulnois, K. N. Timmis, D. Bitter-Suermann. 1985. NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc. Natl. Acad. Sci. USA 82: 1194-1198. [Abstract/Free Full Text]
  19. Muench, M. O., R. Namikawa. 2001. Disparate regulation of human fetal erythropoiesis by the microenvironments of the liver and bone marrow. Blood Cells Mol. Dis. 27: 377-390. [Medline]
  20. Muench, M. O., J. G. Schneider, M. A. Moore. 1992. Interactions among colony-stimulating factors, IL-1β, IL-6, and kit-ligand in the regulation of primitive murine hematopoietic cells. Exp. Hematol. 20: 339-349. [Medline]
  21. Ramsdell, F., J. C. Zuniga-Pflucker, Y. Takahama. 2006. In vitro systems for the study of T cell development: fetal thymus organ culture and OP9-DL1 cell coculture. J. E. Coligan, 2nd, ed. Current Protocols in Immunology 3.18.11-13.18.17. John Wiley & Sons, New York, NY.
  22. Eng, J., A. L. McCormack, J. R. Yates, 3rd. 1994. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass. Spectrom. 5: 976-989.
  23. Tuckermann, J. P., A. Kleiman, R. Moriggl, R. Spanbroek, A. Neumann, A. Illing, B. E. Clausen, B. Stride, I. Forster, A. J. Habenicht, et al 2007. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J. Clin. Invest. 117: 1381-1390. [Medline]
  24. Chen, L., J. Sundback, S. Olofsson, M. Jondal. 2006. Interference with O-glycosylation in RMA lymphoma cells leads to a reduced in vivo growth of the tumor. Int. J. Cancer 119: 1495-1500. [Medline]
  25. Habu, S., H. Fukui, K. Shimamura, M. Kasai, Y. Nagai, K. Okumura, N. Tamaoki. 1981. In vivo effects of anti-asialo GM1: I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol. 127: 34-38. [Abstract]
  26. Husmann, M., T. Pietsch, B. Fleischer, C. Weisgerber, D. Bitter-Suermann. 1989. Embryonic neural cell adhesion molecules on human natural killer cells. Eur. J. Immunol. 19: 1761-1763. [Medline]
  27. Moebius, J. M., D. Widera, J. Schmitz, C. Kaltschmidt, C. Piechaczek. 2007. Impact of polysialylated CD56 on natural killer cell cytotoxicity. BMC Immunol. 8: 13[Medline]
  28. Poongodi, G. L., N. Suresh, S. C. Gopinath, T. Chang, S. Inoue, Y. Inoue. 2002. Dynamic change of neural cell adhesion molecule polysialylation on human neuroblastoma (IMR-32) and rat pheochromocytoma (PC-12) cells during growth and differentiation. J. Biol. Chem. 277: 28200-28211. [Abstract/Free Full Text]
  29. Chalifour, A., P. Jeannin, J. F. Gauchat, A. Blaecke, M. Malissard, T. N'Guyen, N. Thieblemont, Y. Delneste. 2004. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers {alpha}-defensin production. Blood 104: 1778-1783. [Abstract/Free Full Text]
  30. Kougias, P., H. Chai, P. H. Lin, Q. Yao, A. B. Lumsden, C. Chen. 2005. Defensins and cathelicidins: neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis. J. Cell. Mol. Med. 9: 3-10. [Medline]
  31. Gallo, R. L., K. J. Kim, M. Bernfield, C. A. Kozak, M. Zanetti, L. Merluzzi, R. Gennaro. 1997. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J. Biol. Chem. 272: 13088-13093. [Abstract/Free Full Text]
  32. Jenssen, H., P. Hamill, R. E. Hancock. 2006. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19: 491-511. [Abstract/Free Full Text]
  33. Malmsten, M., M. Davoudi, B. Walse, V. Rydengard, M. Pasupuleti, M. Morgelin, A. Schmidtchen. 2007. Antimicrobial peptides derived from growth factors. Growth Factors 25: 60-70. [Medline]
  34. Rock, K. L., H. Kono. 2008. The inflammatory response to cell death. Annu. Rev. Pathol. 3: 99-126. [Medline]
  35. Bitter-Suermann, D., J. Roth. 1987. Monoclonal antibodies to polysialic acid reveal epitope sharing between invasive pathogenic bacteria, differentiating cells and tumor cells. Immunol. Res. 6: 225-237. [Medline]
  36. Miyahara, R., F. Tanaka, T. Nakagawa, K. Matsuoka, K. Isii, H. Wada. 2001. Expression of neural cell adhesion molecules (polysialylated form of neural cell adhesion molecule and L1-cell adhesion molecule) on resected small cell lung cancer specimens: in relation to proliferation state. J. Surg. Oncol. 77: 49-54. [Medline]
  37. Suzuki, M., M. Suzuki, J. Nakayama, A. Suzuki, K. Angata, S. Chen, K. Sakai, K. Hagihara, Y. Yamaguchi, M. Fukuda. 2005. Polysialic acid facilitates tumor invasion by glioma cells. Glycobiology 15: 887-894. [Abstract/Free Full Text]
  38. Devi, S. J., J. B. Robbins, R. Schneerson. 1991. Antibodies to poly[(2 -> 8)-{alpha}-N-acetylneuraminic acid] and poly[(2 -> 9)-{alpha}-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc. Natl. Acad. Sci. USA 88: 7175-7179. [Abstract/Free Full Text]
  39. Mushtaq, N., M. B. Redpath, J. P. Luzio, P. W. Taylor. 2004. Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype. Antimicrob. Agents Chemother. 48: 1503-1508. [Abstract/Free Full Text]
  40. Yang, D., A. Biragyn, L. W. Kwak, J. J. Oppenheim. 2002. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 23: 291-296. [Medline]



This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
P. M. Drake, C. M. Stock, J. K. Nathan, P. Gip, K. P. K. Golden, B. Weinhold, R. Gerardy-Schahn, and C. R. Bertozzi
Polysialic acid governs T-cell development by regulating progenitor access to the thymus
PNAS, July 21, 2009; 106(29): 11995 - 12000.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. J. Morley, L. M. Willis, C. Whitfield, W. W. Wakarchuk, and S. G. Withers
A New Sialidase Mechanism: BACTERIOPHAGE K1F ENDO-SIALIDASE IS AN INVERTING GLYCOSIDASE
J. Biol. Chem., June 26, 2009; 284(26): 17404 - 17410.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drake, P. M.
Right arrow Articles by Bertozzi, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drake, P. M.
Right arrow Articles by Bertozzi, C. R.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Stem Cells

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS